Cyuan-Yi Yeh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Cyuan-Yi Yeh has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
Alan Y. Hsu
Department of General Medicine, China Medical University Hospital, Taichung, Taiwan
1 shared publicationChao-Chien Hu
Department of Ophthalmology, Shin Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan
1 shared publication- Cheng-Kuo Cheng
Department of Ophthalmology, Shin Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan
1 shared publication - Chun-Ju Lin
Department of Ophthalmology, China Medical University Hospital China Medical University Taichung Taiwan
1 shared publication Hou-Ting Kuo
Department of General Medicine, China Medical University Hospital, Taichung, Taiwan
1 shared publication- Hwa-Shin Fang
Shin-Kong Wu Ho-Su Memorial Hospital
1 shared publication
Latest Publications
The impact of opioid, cannabis and cocaine use disorder on the risk of diabetic retinopathy in patients with type 2 diabetes mellitus
Background and aims: Opioid use disorder (OUD), cannabis use disorder (CUD) and cocaine use disorder have been associated with a range of adverse health outcomes, including certain ocular manifestations; however, their impact on diabetic retinopathy (DR) remains insufficiently explored. This study aimed to measure the association between OUD, CUD and cocaine use disorder and the risk of DR among patients with type 2 diabetes mellitus (T2DM). Design: Propensity‐score‐matched retrospective cohort study. Setting: This study used the TriNetX US Collaborative Network to access electronic health records (EHRs), including data on demographics, diagnoses, medication use and laboratory results. Participants/cases: A total of 131 088 adult patients with T2DM and comorbid OUD, CUD or cocaine use disorder, and 131 088 adult patients with T2DM without these conditions, were identified following propensity score matching. Measurements: The primary outcome was the risk of DR evaluated over a 5‐year follow‐up period. The risks of various DR subtypes and diabetic macular edema (DME) were also assessed. Hazard ratios (HRs) with 95% confidence intervals (CIs) were calculated. Findings: Over a 5‐year follow‐up period, patients with T2DM comorbid with OUD, CUD or cocaine use disorder had a statistically significantly higher risk of developing DR [HR (95% CI) = 2.90 (2.55–3.30), P < 0.00] compared with those without any drug use disorder. Drug use disorders were also associated with elevated risks of vision‐threatening diabetic retinopathy (VTDR) [HR (95% CI) = 2.78 (2.24–3.46), P < 0.00], non‐proliferative diabetic retinopathy (NPDR) [HR (95% CI) = 3.10 (2.61–3.68), P < 0.00], proliferative diabetic retinopathy (PDR) [HR (95% CI) = 3.17 (2.26–4.45), P < 0.00] and DME [HR (95% CI) = 2.64 (2.04–3.42), P < 0.00] among patients with T2DM. Conclusions: Opioid use disorder, cannabis use disorder and cocaine use disorder appear to be associated with an elevated risk of diabetic retinopathy among patients with type 2 diabetes mellitus.
The impact of opioid, cannabis and cocaine use disorder on the risk of diabetic retinopathy in patients with type 2 diabetes mellitus
Background and aims: Opioid use disorder (OUD), cannabis use disorder (CUD) and cocaine use disorder have been associated with a range of adverse health outcomes, including certain ocular manifestations; however, their impact on diabetic retinopathy (DR) remains insufficiently explored. This study aimed to measure the association between OUD, CUD and cocaine use disorder and the risk of DR among patients with type 2 diabetes mellitus (T2DM). Design: Propensity‐score‐matched retrospective cohort study. Setting: This study used the TriNetX US Collaborative Network to access electronic health records (EHRs), including data on demographics, diagnoses, medication use and laboratory results. Participants/cases: A total of 131 088 adult patients with T2DM and comorbid OUD, CUD or cocaine use disorder, and 131 088 adult patients with T2DM without these conditions, were identified following propensity score matching. Measurements: The primary outcome was the risk of DR evaluated over a 5‐year follow‐up period. The risks of various DR subtypes and diabetic macular edema (DME) were also assessed. Hazard ratios (HRs) with 95% confidence intervals (CIs) were calculated. Findings: Over a 5‐year follow‐up period, patients with T2DM comorbid with OUD, CUD or cocaine use disorder had a statistically significantly higher risk of developing DR [HR (95% CI) = 2.90 (2.55–3.30), P < 0.00] compared with those without any drug use disorder. Drug use disorders were also associated with elevated risks of vision‐threatening diabetic retinopathy (VTDR) [HR (95% CI) = 2.78 (2.24–3.46), P < 0.00], non‐proliferative diabetic retinopathy (NPDR) [HR (95% CI) = 3.10 (2.61–3.68), P < 0.00], proliferative diabetic retinopathy (PDR) [HR (95% CI) = 3.17 (2.26–4.45), P < 0.00] and DME [HR (95% CI) = 2.64 (2.04–3.42), P < 0.00] among patients with T2DM. Conclusions: Opioid use disorder, cannabis use disorder and cocaine use disorder appear to be associated with an elevated risk of diabetic retinopathy among patients with type 2 diabetes mellitus.
- Open Access
- 1 January 2025
- Published by Wiley in Journal of Ophthalmology
- Vol. 2025 (1) , 9490950
Influencing Factors in Corneal Densitometry Recovery After Accelerated Cross‐Linking for Keratoconus
This study examines corneal densitometry recovery and influencing factors following accelerated corneal cross‐linking (CXL) for progressive keratoconus. Corneal densitometry, measured using Scheimpflug tomography, provides an objective assessment of corneal clarity, especially in tracking the resolution of postoperative haze. We conducted a retrospective case‐control analysis of 24 patients (31 eyes) who underwent CXL with 0.25% riboflavin and 18 mW/cm 2 irradiation between 2021 and 2023. Variables included patient age, maximum keratometry ( K max ), central corneal thickness (CCT), and demarcation line depth (DLD), defined as the depth of the CXL region. Results revealed a significant increase in densitometry values across most corneal zones at 1‐month postoperation, followed by a gradual return to baseline by 12 months. Notably, younger patients exhibited a faster recovery, with mean densitometry values returning to baseline in 11.4 months compared to 14.9 months in older patients ( p = 0.02). Similarly, corneas with deeper DLDs demonstrated faster densitometry recovery, suggesting a potentially more efficient corneal remodeling process. Additional analysis indicated a trend toward higher densitometry values in shallower DLDs at 1 month, although this difference was not statistically significant. These findings support the use of densitometry as a reliable measure of post‐CXL healing. While DLD depth and patient age were associated with a faster recovery, they did not directly predict final corneal clarity. Our study suggests that factors such as age and DLD depth should be considered in patient prognosis, although further research is needed to confirm these findings across varying CXL protocols.
- 1 January 2025
- Published by Wiley in Journal of Ophthalmology
- Vol. 2025 (1) , 9490950
Open AccessInfluencing Factors in Corneal Densitometry Recovery After Accelerated Cross‐Linking for Keratoconus
This study examines corneal densitometry recovery and influencing factors following accelerated corneal cross‐linking (CXL) for progressive keratoconus. Corneal densitometry, measured using Scheimpflug tomography, provides an objective assessment of corneal clarity, especially in tracking the resolution of postoperative haze. We conducted a retrospective case‐control analysis of 24 patients (31 eyes) who underwent CXL with 0.25% riboflavin and 18 mW/cm 2 irradiation between 2021 and 2023. Variables included patient age, maximum keratometry ( K max ), central corneal thickness (CCT), and demarcation line depth (DLD), defined as the depth of the CXL region. Results revealed a significant increase in densitometry values across most corneal zones at 1‐month postoperation, followed by a gradual return to baseline by 12 months. Notably, younger patients exhibited a faster recovery, with mean densitometry values returning to baseline in 11.4 months compared to 14.9 months in older patients ( p = 0.02). Similarly, corneas with deeper DLDs demonstrated faster densitometry recovery, suggesting a potentially more efficient corneal remodeling process. Additional analysis indicated a trend toward higher densitometry values in shallower DLDs at 1 month, although this difference was not statistically significant. These findings support the use of densitometry as a reliable measure of post‐CXL healing. While DLD depth and patient age were associated with a faster recovery, they did not directly predict final corneal clarity. Our study suggests that factors such as age and DLD depth should be considered in patient prognosis, although further research is needed to confirm these findings across varying CXL protocols.
- 14 November 2024
- Published by SAGE Publications in European Journal of Ophthalmology
- Vol. 35 (3) , 785-798
Accelerated versus conventional corneal collagen cross-linking for keratoconus: A meta-analysis of randomized controlled trials
Purpose: To systematically compare the effectiveness of conventional corneal collagen cross-linking (CCXL) protocols and accelerated corneal collagen cross-linking (ACXL) protocols in cases with progressive keratoconus. Methods: The Cochrane library, EMBASE, MEDLINE, PubMed, and Web of Science databases were searched for randomized controlled trials (RCTs). Outcomes were clinical results and changes in corneal properties. Standardized mean differences (SMD) and 95% confidence interval (CI) were used to estimate the clinical consequences. All outcomes were distributed by different follow-up durations (6 months, 12 months, and > 12 months). We also compared maximum keratometry (Kmax) and best spectacle-corrected visual acuity (BCVA) in subgroups, which were categorized by the discrepant impregnation time period of riboflavin. Results: We included 14 RCTs that met the eligibility criteria in this meta-analysis. At the last follow-up, CCXL was superior in postoperative change in demarcation line (SMD: −1.573; 95% CI: −2.897 to −0.248) and in Kmax (SMD:0.302; 95% CI: 0.071 to 0.533), whereas ACXL provided a significantly lower reduction in central corneal thickness (SMD: 0.498; 95% CI: 0.125 to 0.871). No differences in the changes in uncorrected visual acuity, BCVA, manifest refraction spherical equivalent, corneal biomechanical properties, and the endothelial cell density were found among both groups. Conclusion: CCXL was superior to ACXL in greater corneal flattening and deeper demarcation line, while ACXL seemed to cause less reduction in CCT and allow for earlier UDVA stability. To clearly define the comparative safety and clinical consequences of the different regimens of CXL, more RCTs are required.
- 14 November 2024
- Published by SAGE Publications in European Journal of Ophthalmology
- Vol. 35 (3) , 785-798
Accelerated versus conventional corneal collagen cross-linking for keratoconus: A meta-analysis of randomized controlled trials
Purpose: To systematically compare the effectiveness of conventional corneal collagen cross-linking (CCXL) protocols and accelerated corneal collagen cross-linking (ACXL) protocols in cases with progressive keratoconus. Methods: The Cochrane library, EMBASE, MEDLINE, PubMed, and Web of Science databases were searched for randomized controlled trials (RCTs). Outcomes were clinical results and changes in corneal properties. Standardized mean differences (SMD) and 95% confidence interval (CI) were used to estimate the clinical consequences. All outcomes were distributed by different follow-up durations (6 months, 12 months, and > 12 months). We also compared maximum keratometry (Kmax) and best spectacle-corrected visual acuity (BCVA) in subgroups, which were categorized by the discrepant impregnation time period of riboflavin. Results: We included 14 RCTs that met the eligibility criteria in this meta-analysis. At the last follow-up, CCXL was superior in postoperative change in demarcation line (SMD: −1.573; 95% CI: −2.897 to −0.248) and in Kmax (SMD:0.302; 95% CI: 0.071 to 0.533), whereas ACXL provided a significantly lower reduction in central corneal thickness (SMD: 0.498; 95% CI: 0.125 to 0.871). No differences in the changes in uncorrected visual acuity, BCVA, manifest refraction spherical equivalent, corneal biomechanical properties, and the endothelial cell density were found among both groups. Conclusion: CCXL was superior to ACXL in greater corneal flattening and deeper demarcation line, while ACXL seemed to cause less reduction in CCT and allow for earlier UDVA stability. To clearly define the comparative safety and clinical consequences of the different regimens of CXL, more RCTs are required.
- 1 October 2024
- Published by Wolters Kluwer Health in Journal of Cataract & Refractive Surgery
- Vol. 50 (10) , 1074-1082
Comparison of low-energy FLACS and conventional cataract surgery: meta-analysis and systematic review
Topic: To systematically compare the effectiveness of conventional phacoemulsification surgery (CPS) and low-energy femtosecond laser–assisted cataract surgery (FLACS) in patients with cataract. Clinical Relevance: Cataract surgery is a common procedure, and comparing different techniques such as CPS and low-energy FLACS is crucial for optimizing patient outcomes. Methods: The PubMed, Web of Science, MEDLINE, EMBASE, and Cochrane library databases were searched for clinical trials. Outcomes of procedure time, effective phacoemulsification time, balanced salt solution usage, cumulative dissipated energy, mean change of corrected distance visual acuity, endothelial cells reduction, central corneal thickness (CCT), and aqueous cytokine level were evaluated. The effect measures were weighted mean differences with 95% CI. The protocol was registered at the Prospective Register for Systematic Reviews (registration number CRD42023420173). Results: 11 studies were included in this meta-analysis, of which 1680 eyes were analyzed (637 eyes in the low-energy FLACS group and 1043 eyes in the CPS group). Low-energy FLACS demonstrated significantly fewer reductions in endothelial cell count at 6 months (P < .001) compared with CPS. It also exhibited a shorter effective phacoemulsification time (P < .001) and less balanced salt solution usage (P < .001). However, there were no differences in cumulative dissipated energy, corrected distance visual acuity, CCT changes, or aqueous cytokine levels between the 2 groups. Conclusions: Both low-energy FLACS and CPS are effective in treating cataracts, but low-energy FLACS may offer advantages such as reduced phacoemulsification time and less endothelial cell loss.
- 1 October 2024
- Published by Wolters Kluwer Health in Journal of Cataract & Refractive Surgery
- Vol. 50 (10) , 1074-1082
Comparison of low-energy FLACS and conventional cataract surgery: meta-analysis and systematic review
Topic: To systematically compare the effectiveness of conventional phacoemulsification surgery (CPS) and low-energy femtosecond laser–assisted cataract surgery (FLACS) in patients with cataract. Clinical Relevance: Cataract surgery is a common procedure, and comparing different techniques such as CPS and low-energy FLACS is crucial for optimizing patient outcomes. Methods: The PubMed, Web of Science, MEDLINE, EMBASE, and Cochrane library databases were searched for clinical trials. Outcomes of procedure time, effective phacoemulsification time, balanced salt solution usage, cumulative dissipated energy, mean change of corrected distance visual acuity, endothelial cells reduction, central corneal thickness (CCT), and aqueous cytokine level were evaluated. The effect measures were weighted mean differences with 95% CI. The protocol was registered at the Prospective Register for Systematic Reviews (registration number CRD42023420173). Results: 11 studies were included in this meta-analysis, of which 1680 eyes were analyzed (637 eyes in the low-energy FLACS group and 1043 eyes in the CPS group). Low-energy FLACS demonstrated significantly fewer reductions in endothelial cell count at 6 months (P < .001) compared with CPS. It also exhibited a shorter effective phacoemulsification time (P < .001) and less balanced salt solution usage (P < .001). However, there were no differences in cumulative dissipated energy, corrected distance visual acuity, CCT changes, or aqueous cytokine levels between the 2 groups. Conclusions: Both low-energy FLACS and CPS are effective in treating cataracts, but low-energy FLACS may offer advantages such as reduced phacoemulsification time and less endothelial cell loss.
- 1 December 2023
- Published by SAGE Publications in Journal of Ocular Pharmacology and Therapeutics
- Vol. 39 (10) , 705-715
Clinical Efficacy of Omidenepag Isopropyl for Primary Open-Angle Glaucoma, Normal Tension Glaucoma, or Ocular Hypertension: A Meta-Analysis
Purpose: To investigate the clinical efficacy of omidenepag isopropyl (OMDI) among glaucoma patients in terms of increased intraocular pressure (IOP) changes through a meta-analysis. Methods: Studies investigating the clinical efficacy of OMDI toward glaucoma patients were systemically searched. Inclusion criteria include recruiting studies that consisted of glaucoma or normal tension glaucoma patients who received OMDI treatment at least 4 weeks in duration. The primary outcome was to compare changes in IOP levels at baseline before OMDI treatment and after OMDI treatment. Results: Six studies were included with a total of 358 eyes. Our results showed OMDI monotherapy resulted in significant decreased IOP among patients with ocular hypertension, with weighted mean difference post-OMDI treatment being −4.684 (95% confidence interval: −6.010 to −3.358) and I2 of 91.092%. Separate subgroup analyses also showed initial IOP greater than 21 mmHg and those within the age group greater than 65 years old to be correlated with significant reduction in IOP post-OMDI. Randomized control trial (RCTs) design was also found to be superior compared with non-RCT in terms of investigating IOP changes after OMDI. The country of origin of the recruited studies and OMDI dosage frequencies were also found to have no effect on overall IOP changes after OMDI treatment. Conclusions: The current meta-analysis indicates OMDI to be a clinically effective treatment for glaucoma patients in terms of lowering IOP levels.
- 1 December 2023
- Published by SAGE Publications in Journal of Ocular Pharmacology and Therapeutics
- Vol. 39 (10) , 705-715
Clinical Efficacy of Omidenepag Isopropyl for Primary Open-Angle Glaucoma, Normal Tension Glaucoma, or Ocular Hypertension: A Meta-Analysis
Purpose: To investigate the clinical efficacy of omidenepag isopropyl (OMDI) among glaucoma patients in terms of increased intraocular pressure (IOP) changes through a meta-analysis. Methods: Studies investigating the clinical efficacy of OMDI toward glaucoma patients were systemically searched. Inclusion criteria include recruiting studies that consisted of glaucoma or normal tension glaucoma patients who received OMDI treatment at least 4 weeks in duration. The primary outcome was to compare changes in IOP levels at baseline before OMDI treatment and after OMDI treatment. Results: Six studies were included with a total of 358 eyes. Our results showed OMDI monotherapy resulted in significant decreased IOP among patients with ocular hypertension, with weighted mean difference post-OMDI treatment being −4.684 (95% confidence interval: −6.010 to −3.358) and I2 of 91.092%. Separate subgroup analyses also showed initial IOP greater than 21 mmHg and those within the age group greater than 65 years old to be correlated with significant reduction in IOP post-OMDI. Randomized control trial (RCTs) design was also found to be superior compared with non-RCT in terms of investigating IOP changes after OMDI. The country of origin of the recruited studies and OMDI dosage frequencies were also found to have no effect on overall IOP changes after OMDI treatment. Conclusions: The current meta-analysis indicates OMDI to be a clinically effective treatment for glaucoma patients in terms of lowering IOP levels.